Takeda Pharmaceutical (TAK) Capital Expenditures (QoQ) (2018 - 2026)
Takeda Pharmaceutical (TAK) Capital Expenditures (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117.32% |
| Mar 31, 2026 | 820.43% |
| Dec 31, 2025 | 0.58% |
| Sep 30, 2025 | 17.82% |
| Jun 30, 2025 | -114.32% |
| Mar 31, 2025 | 879.71% |
| Dec 31, 2024 | 10.58% |
| Sep 30, 2024 | 10.11% |
| Jun 30, 2024 | -117.85% |
| Mar 31, 2024 | 748.93% |
| Dec 31, 2023 | -21.54% |
| Sep 30, 2023 | 21.85% |
| Jun 30, 2023 | -118.07% |
| Mar 31, 2023 | 883.66% |
| Dec 31, 2022 | -11.66% |
| Sep 30, 2022 | 34.87% |
| Jun 30, 2022 | -117.95% |
| Mar 31, 2022 | 862.09% |
| Dec 31, 2021 | 14.78% |
| Sep 30, 2021 | -2.52% |